Table 2.

Ongoing radiation clinical trials.

Study	Phase	Therapy	Population
NSABP B-51/RTOG1304 NCT01872975	III	RNI vs. no RNI	Clinically node-positive who achieve pCR post NAC
Alliance A011202 NCT01901094	III	ALND vs. axillary radiation	NAC and positive SLNB
NRG BR007 (DEBRA) NCT04852887	III	De-escalation of radiation after BCS	Stage I, HR+, HER2−, Oncotype ≤ 18
CCTG MA.39 TAILOR RT NCT03488693	III	Regional radiotherapy in biomarker low-risk, node-positive breast cancer	ER+, HER2− 1–3LN+, Oncotype ≤ 18
the NRG-BR008 (“HERO”) NCT05705401	III	BCS > adjuvant HER2-directed therapy followed by radiation vs. no radiation	early-stage, low risk, HER2-positive breast cancer
ALLIANCE 221505 (RT CHARM) NCT03414970	III	hypofractionated post-mastectomy radiation with breast reconstruction to evaluate safety and radiation-related complications	Patients who had a mastectomy and reconstructive surgery

pCR: pathologic complete response, ALND: axillary lymph node dissection, NAC: neoadjuvant chemotherapy, SLNB: sentinel lymph node biopsy, BCS: breast conserving surgery, HR: hormone receptor, ER: estrogen receptor, LN: lymph node.